HIV-1-infection Clinical Trial
Official title:
Improving Vaginal Health to Decrease Biological Risk of HIV-1 Infection in Canadian African, Caribbean and Black (ACB) Women: Estrogen and Probiotic Treatment for Vaginal Health
Verified date | December 2021 |
Source | McMaster University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will enrol African, Caribbean and Black (ACB) women who are known to have a more diverse vaginal microbiome, higher rates of bacterial vaginosis with lower numbers of protective lactobacilli, and are at increased risk for HIV. The investigators will evaluate the safety, feasibility, effect on the vaginal bacterial microbiome and changes in local immune and inflammatory responses with the administration of vaginal estrogen alone, vaginal estrogen in combination with oral or vaginally administered probiotics, or vaginal probiotics alone.
Status | Completed |
Enrollment | 50 |
Est. completion date | December 14, 2021 |
Est. primary completion date | December 14, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - African, Caribbean, Black - Pre-menopausal women in good general health, as determined by the investigator - Uterus and cervix present - Negative pregnancy test - Currently practicing barrier or non-hormonal forms of contraception, and planning to continue, for the duration of the study (barrier contraceptive, abstinence) - Willing to undergo a pelvic exam by a female nurse/female doctor - Willing to abstain from vaginal intercourse for 48 hours prior to sampling, over the entire course of the study - Able to understand, comply and consent to protocol requirements and instructions - Able to attend scheduled study visits and complete required investigations Exclusion Criteria: - Currently lactating - Pregnant: suspected, current or in the last 12 months - Irregular menstrual cycle (less than 6 periods in a year) not related to contraceptive use, pregnancy or breastfeeding - Post-menopausal - Hormonal Contraceptive use or other hormonal treatment in the past 3 months - Current Intra-Uterine Device (IUD) use - Positive test result for Gonorrhea and/or Chlamydia - Clinically obvious genital ulceration/lesions - Symptomatic vaginal yeast infection or clinically significant vaginal discharge - HIV-positive - Any clinically significant abnormality on screening safety blood tests, that in the opinion of the investigator would preclude enrolment. - Diagnosed blood clotting disorder - Any genital tract procedure (e.g. biopsy) within the past 6 months - Use of oral probiotic supplement, oral antibiotics or oral steroids within the past 30 days - Current use of any vaginal products (except tampons) such as spermicides, microbicides, douching or drying products, antifungals, or steroids. - Known intolerance of Lactobacillus-containing probiotic supplements - Undiagnosed abnormal genital bleeding - Known, suspected, or history of breast cancer - Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer) - Currently taking immunosuppressive drugs - Known or suspected hypersensitivity to any component of the Estring or RepHresh Pro-B products - Diagnosis of endometrial hyperplasia - Known liver dysfunction or disease; as long as liver function tests have failed to return to normal - Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease) - Partial or complete loss of vision due to ophthalmic vascular disease - Porphyria - Concomitant medication which in the opinion of the investigator may be associated with a significant drug interaction with the estrogen in Estring. - The conditions below are grounds for exclusion based on the opinion of the investigator: 1. Risk factors for estrogen dependent tumours, e.g. first degree heredity for breast cancer 2. Diabetes mellitus with or without vascular involvement 3. Migraine or (severe) headache 4. Epilepsy 5. A history of, or risk factors for, thromboembolic disorders 6. Systemic lupus erythematosus 7. Otosclerosis 8. Cholelithiasis 9. Leiomyoma (uterine fibroids) 10. Endometriosis 11. A history of endometrial hyperplasia 12. Hypertension 13. Asthma 14. Diagnosed anemia |
Country | Name | City | State |
---|---|---|---|
Canada | Women's Health in Women's Hands | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
McMaster University | CIHR Canadian HIV Trials Network |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Refusal rate | Number of eligible participants approached who do not consent to be enrolled | 12 months | |
Primary | Participant retention rate | Number of participants who complete the study as proportion of total number of participants enrolled | 12 months | |
Primary | Incidence of treatment emergent adverse events | The incidence of adverse events, including serious adverse events, their severity and their relationship to study intervention assessed by reviewing case report forms and participant diaries. | 2 months | |
Primary | Rate of adherence | Adherence will be measured by calculating the total probiotic used/total dispensed and for Estring by total days used/total time period | 30 days | |
Secondary | Changes in proportion of Lactobacillus species in the vaginal microbiota | Aliquots of cervico-vaginal lavage (CVL) fluids will undergo microbiome analysis using a modified Illumina sequencing method for bacterial community profiling of 16S rRNA to measure changes from baseline at follow-up sampling. | 30 days | |
Secondary | Change in innate inflammatory cytokine/chemokine levels | Changes from baseline in levels of cytokine/chemokines will be measured in CVL by a 22-plex multiplex assay at 2 and 4 weeks | 30 days | |
Secondary | Changes in number of HIV target cells in the genital tract | Changes from baseline in level of HIV susceptible CD4+ T cells will be quantified using a lab developed HIV pseudovirus assay at 2 and 4 weeks. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03940521 -
Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
|
||
Completed |
NCT03227731 -
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
|
Phase 2/Phase 3 | |
Completed |
NCT03570918 -
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04022967 -
ANRS 12372 MODERATO Study
|
Phase 3 | |
Not yet recruiting |
NCT06282783 -
Studying Topiramate for Re-Activating the HIV-1 Reservoir
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06337032 -
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
|
Phase 4 | |
Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
Recruiting |
NCT03536234 -
Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
|
Phase 2 | |
Completed |
NCT04340388 -
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
|
Phase 4 | |
Withdrawn |
NCT05769569 -
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
|
Phase 1 | |
Enrolling by invitation |
NCT05584397 -
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
|
||
Completed |
NCT04388904 -
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
|
Phase 4 | |
Not yet recruiting |
NCT04894357 -
Impact of V106I on Resistance to Doravirine
|
||
Completed |
NCT04963712 -
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
|
Early Phase 1 | |
Completed |
NCT04568239 -
Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
|
||
Not yet recruiting |
NCT04311944 -
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
|
N/A | |
Not yet recruiting |
NCT04311957 -
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
|
Phase 4 | |
Not yet recruiting |
NCT04513496 -
Telemedicine in HIV Care in Buenos Aires
|
||
Completed |
NCT03998176 -
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
|
Phase 4 |